blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3622066

EP3622066 - HUMAN-ENZYME MEDIATED DEPLETION OF HOMOCYSTEINE FOR TREATING PATIENTS WITH HYPERHOMOCYSTEINEMIA AND HOMOCYSTINURIA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  31.03.2023
Database last updated on 28.03.2026
FormerRequest for examination was made
Status updated on  14.02.2020
FormerThe international publication has been made
Status updated on  17.11.2018
Formerunknown
Status updated on  03.07.2018
Most recent event   Tooltip03.02.2026New entry: Reply to examination report 
Applicant(s)For all designated states
Board of Regents, The University of Texas System
210 West 7th Street
Austin, TX 78701 / US
[2020/12]
Inventor(s)01 / GEORGIOU, George
6405 Williams Ridge Way
Austin, TX 78731 / US
02 / STONE, Everett
7503 Hart Lane
Austin, TX 78731 / US
03 / LU, Wei-Cheng
7600 Wood Hollow Dr. 202
Austin, TX 78731 / US
 [2020/12]
Representative(s)Simmons & Simmons LLP (Munich), et al
Lehel Carré
Gewürzmühlstraße 11
80538 Munich / DE
[N/P]
Former [2020/12]Nottrott, Stephanie
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Prinzregentenstraße 68
81675 München / DE
Application number, filing date18732985.911.05.2018
[2020/12]
WO2018US32246
Priority number, dateUS201762505493P12.05.2017         Original published format: US 201762505493 P
[2020/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018209192
Date:15.11.2018
Language:EN
[2018/46]
Type: A1 Application with search report 
No.:EP3622066
Date:18.03.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 15.11.2018 takes the place of the publication of the European patent application.
[2020/12]
Search report(s)International search report - published on:EP15.11.2018
ClassificationIPC:C12N9/88, A61K38/00
[2020/12]
CPC:
A61K38/51 (EP,IL,KR,US); C12N9/96 (EP,IL,KR,US); C12N9/88 (EP,IL,KR,US);
A61K31/198 (EP,IL,KR,US); A61K31/4415 (EP,IL,KR,US); A61K47/60 (IL,KR,US);
A61K9/0019 (EP,IL,KR,US); A61K9/19 (EP,IL,KR,US); A61P7/00 (EP,IL,KR,US);
C12N15/70 (IL,US); C12N15/80 (IL,US); C12N15/861 (IL,US);
C12N15/867 (IL,US); C12N15/869 (IL,US); C12Y404/01001 (EP,IL,KR,US);
Y02A50/30 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/12]
TitleGerman:HUMANENZYMVERMITTELTE DEPLETION VON HOMOCYSTEIN ZUR BEHANDLUNG VON PATIENTEN MIT HYPERHOMOCYSTEINÄMIE UND HOMOCYSTINURIE[2020/12]
English:HUMAN-ENZYME MEDIATED DEPLETION OF HOMOCYSTEINE FOR TREATING PATIENTS WITH HYPERHOMOCYSTEINEMIA AND HOMOCYSTINURIA[2020/12]
French:DÉPLÉTION D'HOMOCYSTÉINE, MÉDIÉE PAR UNE ENZYME HUMAINE, POUR LE TRAITEMENT DE PATIENTS ATTEINTS D'HYPERHOMOCYSTÉINÉMIE ET D'HOMOCYSTINURIE[2020/12]
Entry into regional phase11.12.2019National basic fee paid 
11.12.2019Designation fee(s) paid 
11.12.2019Examination fee paid 
Examination procedure11.12.2019Examination requested  [2020/12]
11.12.2019Date on which the examining division has become responsible
30.07.2020Amendment by applicant (claims and/or description)
04.04.2023Despatch of a communication from the examining division (Time limit: M04)
09.08.2023Reply to a communication from the examining division
27.08.2024Despatch of a communication from the examining division (Time limit: M02)
23.10.2024Reply to a communication from the examining division
01.10.2025Despatch of a communication from the examining division (Time limit: M04)
30.01.2026Reply to a communication from the examining division
Fees paidRenewal fee
26.05.2020Renewal fee patent year 03
12.05.2021Renewal fee patent year 04
16.03.2022Renewal fee patent year 05
14.03.2023Renewal fee patent year 06
13.03.2024Renewal fee patent year 07
01.05.2025Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I] WO2015031726  (UNIV TEXAS et al.)
 [A] WO2011097381  (USE UNIVERSITY OF TEXAS SYSTEM BOARD OF et al.)
 [I]   PALEY O M: "Engineering a Novel Human Methionine Degrading Enzyme as a Broadly Effecive Cancer Therapeutic", 1 August 2014 (2014-08-01), Dissertation, University of Texas, Austin, US, XP055493029, Retrieved from the Internet [retrieved on 20180717]
by applicantUS9481877
 US2009304666
 US5889155
 US4870287
 US5739169
 US5760395
 US5801005
 US5824344
 US5830880
 US5846945
 US8709407
 US2011200576
   "Remington's Pharmaceutical Sciences", 1990
   ASHE ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 57, 1974, pages 417
   AUSTIN-WARD; VILLASECA, REVISTAMEDICA DE CHILE, vol. 126, no. 7, 1998, pages 838 - 845
   AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1994, GREENE PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
   BREILLOUT ET AL.: "Methionine dependency of malignant tumors: a possible approach for therapy", 1990, OXFORD UNIVERSITY PRESS, pages: 1628 - 1632
   BUKOWSKI ET AL., CLINICAL CANCER RES., vol. 4, no. 10, 1998, pages 2337 - 2347
   CHRISTODOULIDES ET AL., MICROBIOLOGY, vol. 144, 1998, pages 3027 - 3037
   DAVIDSON ET AL., J. IMMUNOTHER., vol. 21, no. 5, 1998, pages 389 - 398
   ESAKI; SODA, METHODS ENZYMOL., vol. 143, 1987, pages 459
   GILL; HIPPEL: "Calculation of protein extinction coefficients from amino acid sequence data", ANAL BIOCHEM, vol. 182, no. 2, 1989, pages 319 - 326, XP024820625, DOI: doi:10.1016/0003-2697(89)90602-7

DOI:   http://dx.doi.org/10.1016/0003-2697(89)90602-7
   HALPERN ET AL., PROC. NATL. ACAD. SCI., vol. 71, 1974, pages 1133 - 1136
   HANIBUCHI ET AL., INT. J. CANCER, vol. 78, no. 4, 1998, pages 480 - 485
   HARKKI ET AL., BIOTECHNOLOGY, vol. 7, 1989, pages 596 - 603
   HELLSTRAND ET AL., ACTA ONCOLOGICA, vol. 37, no. 4, 1998, pages 347 - 353
   HOLLANDER, FRONT. IMMUN., vol. 3, 2012, pages 3
   HOOVER; LUBKOWSKI: "DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis", NUCLEIC ACIDS RES., vol. 30, 2002
   HOPWOOD ET AL.: "Genetic Manipulation of Streptomyces", 1985, A LABORATORY MANUAL, THE JOHN INNES FOUNDATION, article "Genetic Manipulation of Streptomyces"
   HORI ET AL., CANCER RES., vol. 56, 1996, pages 2116 - 2122
   HUI; HASHIMOTO, INFECTION IMMUN, vol. 66, no. 11, 1998, pages 5329 - 5336
   ITO ET AL., BIOCHEM., vol. 79, 1976, pages 1263
   KANG ET AL.: "Homocysteinemia due to folate deficiency", METABOLISM, vol. 36, 1987, pages 458 - 62, XP026309198, DOI: doi:10.1016/0026-0495(87)90043-6

DOI:   http://dx.doi.org/10.1016/0026-0495(87)90043-6
   KREIS; GOODENOW, CANCER RES., vol. 38, 1978, pages 2259 - 2262
   KREIS ET AL., CANCER RES., vol. 40, 1980, pages 634 - 641
   KREIS, CANCER TREATMENT RPTS., vol. 63, 1979, pages 1069
   KRUGER ET AL.: "Cystathionine beta-synthase deficiency in Georgia (USA): correlation of clinical and biochemical phenotype with genotype", HUMAN MUTATION, vol. 22, 2003, pages 434 - 41
   KUDOU ET AL., J. BIOCHEM., vol. 141, 2007, pages 535
   LISHKO ET AL., ANTICANCER RES., vol. 13, 1993, pages 1465 - 1468
   LORDANESCU, J. BACTERIOL, vol. 12, 1975, pages 597 601
   LU ET AL.: "Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase", BIOCHEM. BIOPHYS. RES. COMM., vol. 189, no. 2, 1992, pages 749 - 758, XP002049551, DOI: doi:10.1016/0006-291X(92)92265-Y

DOI:   http://dx.doi.org/10.1016/0006-291X(92)92265-Y
   MANIATIS ET AL.: "Molecular Cloning, A Laboratory Manual", 1988, COLD SPRING HARBOR PRESS
   MELLOR ET AL., GENE, vol. 24, 1983, pages 1 - 14
   MUDD ET AL.: "Homocystinuria: an enzymatic defect", SCIENCE, vol. 143, 1964, pages 1443 - 45
   NAKAMURA, ANAL. BIOCHEM., vol. 138, 1984, pages 421 - 424
   NYGARD ET AL.: "Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 67, 1998, pages 263 - 70
   PENTTILA ET AL., GENE, vol. 61, 1987, pages 155 - 164
   QIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, no. 24, 1998, pages 14411 - 14416
   RAO ET AL.: "Role of the Transsulfuration Pathway and of {gamma}-Cystathionase Activity in the Formation of Cysteine and Sulfate from Methionine in Rat Hepatocytes", JOURNAL OF NUTRITION, vol. 120, no. 8, 1990, pages 837
   "Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
   SIBAKOV ET AL., EUR. J. BIOCHEM., vol. 145, 1984, pages 567 572
   SRIDHAR ET AL., ACTA CRYSTALL. SECTION D: BIOLOG, CRYSTALL., vol. 56, 2000, pages 1665 - 1667
   STEEGBORN ET AL.: "Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 18, 1999, pages 12675, XP000941380, DOI: doi:10.1074/jbc.274.18.12675

DOI:   http://dx.doi.org/10.1074/jbc.274.18.12675
   STONE ET AL.: "De novo engineering of a human cystathionine-y-lyase for systemic L-methionine depletion cancer therapy", ACS CHEMICAL BIOLOGY, vol. 7, no. 11, 2012, pages 1822 - 1829, XP055319839, DOI: doi:10.1021/cb300335j

DOI:   http://dx.doi.org/10.1021/cb300335j
   TAKAKURA ET AL.: "Assay method for antitumor L-methionine -lyase: comprehensive kinetic analysis of the complex reaction with L-methionine", ANALYTICAL BIOCHEMISTRY, vol. 327, no. 2, 2004, pages 233 - 240, XP004499133, DOI: doi:10.1016/j.ab.2004.01.024

DOI:   http://dx.doi.org/10.1016/j.ab.2004.01.024
   TAN ET AL., ANTICANCER RES., vol. 16, 1996, pages 3937 - 3942
   TAN ET AL., ANTICANCER RES., vol. 16, 1996, pages 3931 - 3936
   TAN ET AL., PROTEIN EXPRESS. PURIF, vol. 9, 1997, pages 233 - 245
   TAN ET AL., ANTICANCER RES., vol. 17, 1997, pages 3857 - 3860
   WALTER ET AL.: "Strategies for the treatment of cystathionine beta-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years", EUROPEAN JOURNAL OF PEDIATRICS, vol. 157, 1998, pages S71 - S76
   WARD, PROC, EMBO-ALKO WORKSHOP ON MOLECULAR BIOLOGY OF FILAMENTOUS FUNGI, 1989, pages 119 - 128
   WAWRZYNCZAK; THORPE: "Immunoconjugates, Antibody Conuugates In Radioimaging And Therapy Of Cancer", vol. 28, 1987, OXFORD UNIVERSITY PRESS
   YANG ET AL.: "PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates", AACR, 2004, pages 6673 - 6678
   YANG ET AL.: "Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates", AACR, 2004, pages 2131 - 2138
   YOSHIOKA ET AL., CANCER RES., vol. 58, 1998, pages 2583 - 2587
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.